Drugs / WCK 2349
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02217930 | Aug → Dec 2014 | short QT syndrome | Wockhardt | Completed | No outcome recorded |
| Phase 1 | NCT01875939 | Jun 2013 | — | Wockhardt | Completed | No outcome recorded |
| Phase 1 | NCT04874324 | Mar → May 2011 | — | Wockhardt | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2014-08-31 | Wockhardt | Regulatory Wockhardt’s drug discovery gets a boost with fast track approval by USFDA wockhardt.com ↗
WCK 771 and WCK 2349, the two anti infective drugs from Wockhardt, get QIDP status |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-08-31 | Wockhardt | Wockhardt’s drug discovery gets a boost with fast track approval by USFDA wockhardt.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WCK 2349 | “The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule.” NCT01875939 ↗ |
| Route | Oral | “WCK 2349 1000 mg as an oral dose” NCT01875939 ↗ |